Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic

This article endeavors to clarify the current requirements and status of regulatory approval for chemoprevention (risk reduction) drugs and discusses possible improvements to the regulatory pathway for chemoprevention. Covering a wide range of topics in as much depth as space allows, this report is...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer prevention research (Philadelphia, Pa.) Pa.), 2011-03, Vol.4 (3), p.311-323
Hauptverfasser:	Meyskens, Jr, Frank L, Curt, Gregory A, Brenner, Dean E, Gordon, Gary, Herberman, Ronald B, Finn, Olivera, Kelloff, Gary J, Khleif, Samir N, Sigman, Caroline C, Szabo, Eva
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticarcinogenic Agents - pharmacology Biomarkers, Tumor - metabolism Breast Neoplasms - metabolism Chemoprevention - methods Clinical Trials as Topic Drug Approval Drug Industry - methods Early Detection of Cancer Female Humans Male Medical Oncology - methods Neoplasms - prevention & control Patient Compliance Risk
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!